Summary:
- Connecta Therapeutics has successfully secured €3.1 million in funding to accelerate the clinical development of its lead candidate, CTH120, a potential treatment for Fragile X Syndrome.
- The research focus involves targeting the endocannabinoid system to address the cognitive and behavioral deficits associated with this genetic neurodevelopmental disorder.